Wave Life Sciences 향후 성장
Future 기준 점검 2/6
Wave Life Sciences (는) 각각 연간 8.4% 및 45.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 17.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -145% 로 예상됩니다.
핵심 정보
8.4%
이익 성장률
17.19%
EPS 성장률
| Pharmaceuticals 이익 성장 | 14.2% |
| 매출 성장률 | 45.6% |
| 향후 자기자본이익률 | -144.99% |
| 애널리스트 커버리지 | Good |
| 마지막 업데이트 | 01 May 2026 |
최근 향후 성장 업데이트
Recent updates
Seeking Alpha • May 07
Wave Life Sciences: Good Platform, Mixed Clinical Trial Data, Hold
Summary Wave Life Sciences is advancing stereopure oligonucleotide therapeutics, with WVE-006 (AATD) and WVE-007 (weight loss) as primary near-term value drivers. WVE-006 lags BEAM-302 in efficacy but offers a cleaner safety profile; pivotal 2026 data could narrow the efficacy gap and drive valuation upside. Wave’s $602M cash position supports operations into Q3 2028, with low immediate dilution risk and major catalysts pending for both lead programs. Valuation upside hinges on FDA validation of RNA editing, with risk-adjusted peak sales estimates supporting a potential $5.1B valuation versus a ~$1.4B market cap, with significant clinical trial binary risks. Read the full article on Seeking Alpha
내러티브 업데이트 • May 04
WVE: Obesity Data And 2026 Catalysts Will Shape Future Upside
Analysts have reduced their price targets on Wave Life Sciences, driving an internal fair value estimate from about $34.06 to $22.19 as they factor in updated revenue growth, margin expectations, and pipeline competitiveness against GLP-1 treatments. Analyst Commentary Recent research coverage on Wave Life Sciences has become more mixed, with a cluster of price target cuts around updated obesity data and GLP-1 competition, alongside a smaller group of firms that remain constructive on the pipeline and long term opportunity.
내러티브 업데이트 • Apr 19
WVE: Obesity And AATD Pipeline Progress Will Drive Future Upside
Analysts have reduced the average price target for Wave Life Sciences by about $1, reflecting a mix of lower Street targets after recent obesity and GLP-1 competitiveness concerns, partly offset by a few upward revisions following pipeline updates. Analyst Commentary Recent Street commentary around Wave Life Sciences has been mixed, with several firms cutting price targets and questioning the competitiveness of the obesity and GLP 1 pipeline, while a smaller group of bullish analysts has highlighted potential upside tied to clinical catalysts and management execution.내러티브 업데이트 • Apr 05
WVE: Obesity Pipeline Data And Regulatory Pathways Will Drive Future Upside
Analysts have adjusted the fair value estimate for Wave Life Sciences to $50.75 from $45.17, reflecting updated views on its obesity and AATD pipeline opportunities, as well as a mix of recent price target revisions across the Street. Analyst Commentary Recent research on Wave Life Sciences shows a split tape, with some firms turning more cautious while others highlight potential value in the obesity and AATD programs.내러티브 업데이트 • Mar 22
WVE: Obesity Data And 2026 AATD Milestones Will Drive Future Upside
Analysts have nudged the fair value estimate for Wave Life Sciences to $34.06 from $33.50, reflecting updated views on its obesity and AATD pipeline progress and higher future P/E assumptions informed by recent price target revisions across the Street. Analyst Commentary Street research on Wave Life Sciences is centering on the obesity and AATD programs, with several firms updating their targets and models after recent management meetings and clinical readouts.내러티브 업데이트 • Mar 07
WVE: Obesity Fat Reduction Data Will Drive Future Upside Potential
Analysts have inched their fair value estimate for Wave Life Sciences higher from $33.38 to $33.50. This reflects updated views on WVE-007's obesity program and potential regulatory pathways, as well as the recent cluster of higher Street price targets that highlight upcoming data as a key near term catalyst.내러티브 업데이트 • Feb 20
WVE: INHBE Cardiometabolic Data And AATD Rights Will Drive Future Upside
Analysts have nudged their fair value estimate for Wave Life Sciences higher, with the updated target moving from about $33.06 to $33.38 as they factor in recent bullish coverage, higher Street price targets, and evolving views on revenue growth, margins, and future P/E assumptions. Analyst Commentary Bullish analysts have recently highlighted Wave Life Sciences as a name to watch, with several research shops updating their views and price targets in quick succession.내러티브 업데이트 • Feb 06
WVE: INHBE Fat Reduction And AATD Progress Will Drive Future Upside
Analysts increased their price target on Wave Life Sciences by about $1 to roughly $33 per share, as recent bullish coverage and supportive data for its INHBE-targeting approach and AATD program reinforced confidence in the company's long term potential. This was viewed as justification for a higher fair value estimate despite a slightly higher discount rate and modestly adjusted growth and margin assumptions.내러티브 업데이트 • Jan 22
WVE: Obesity And RNA Editing Progress Will Drive Future Upside Potential
Analysts have lifted their price targets on Wave Life Sciences, with our fair value estimate moving from US$32.60 to about US$45.17. This reflects growing confidence in its INHBE-targeting obesity program, validation of its RNA editing approach versus competitors, and supportive commentary around its Huntington’s disease and weight loss pipelines.내러티브 업데이트 • Jan 08
WVE: INHBE Obesity Program Will Drive Future Upside Potential
Analysts have inched up their fair value estimate for Wave Life Sciences to about $31.93 per share from $31.60. This reflects updated views on the company’s INHBE-targeting obesity program, strengthened competitive position in AATD, and continued interest in its broader genetic medicines pipeline.내러티브 업데이트 • Dec 24
WVE: Obesity RNA Editing Advances Are Expected To Drive Future Upside
Analysts have lifted their fair value estimate for Wave Life Sciences to approximately $31.60 per share from about $27.21, citing strengthened competitive positioning in genetic medicines, positive obesity pipeline data, and limited negative read-throughs from peer setbacks as key drivers. Analyst Commentary Bullish analysts highlight that recent competitive developments in alpha-1 antitrypsin deficiency have effectively de-risked Wave Life Sciences' editing approach, supporting higher confidence in long term market share and cash flow potential.분석 기사 • Dec 16
Subdued Growth No Barrier To Wave Life Sciences Ltd. (NASDAQ:WVE) With Shares Advancing 128%
The Wave Life Sciences Ltd. ( NASDAQ:WVE ) share price has done very well over the last month, posting an excellent...내러티브 업데이트 • Dec 10
WVE: Obesity RNA Editing Breakthrough Is Expected To Drive Future Upside
Analysts have raised their price target on Wave Life Sciences by about $7 per share, reflecting increased confidence in the companys validated RNA editing approach, its expanding obesity pipeline, and its insulated Huntington's disease program despite sector specific setbacks. Analyst Commentary Bullish analysts view recent sector developments as reinforcing Wave Life Sciences competitive positioning, particularly in RNA editing and obesity, and see room for further upside as the company executes on its clinical milestones.분석 기사 • Nov 01
Wave Life Sciences Ltd. (NASDAQ:WVE) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected
Wave Life Sciences Ltd. ( NASDAQ:WVE ) shares have had a really impressive month, gaining 29% after a shaky period...분석 기사 • Sep 14
Wave Life Sciences Ltd. (NASDAQ:WVE) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely
Wave Life Sciences Ltd. ( NASDAQ:WVE ) shares have retraced a considerable 29% in the last month, reversing a fair...분석 기사 • Aug 04
Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Trimmed Their Revenue Forecasts By 13%
One thing we could say about the analysts on Wave Life Sciences Ltd. ( NASDAQ:WVE ) - they aren't optimistic, having...분석 기사 • Jul 31
Wave Life Sciences Ltd.'s (NASDAQ:WVE) 26% Share Price Surge Not Quite Adding Up
Wave Life Sciences Ltd. ( NASDAQ:WVE ) shareholders would be excited to see that the share price has had a great month...분석 기사 • Jul 07
We Think Wave Life Sciences (NASDAQ:WVE) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although...분석 기사 • Jun 01
Risks Still Elevated At These Prices As Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Dive 26%
Unfortunately for some shareholders, the Wave Life Sciences Ltd. ( NASDAQ:WVE ) share price has dived 26% in the last...분석 기사 • Apr 04
Wave Life Sciences Ltd.'s (NASDAQ:WVE) 41% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Unfortunately for some shareholders, the Wave Life Sciences Ltd. ( NASDAQ:WVE ) share price has dived 41% in the last...Seeking Alpha • Mar 27
Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531
Summary Wave Life Sciences Ltd. release of multi-dose data from the phase 1b/2a open-label RestorAAtion-2 study, using WVE-006 for AATD-related lung disease, expected in 2025. Positive results were achieved in the phase 2 FORWARD-53 study, using WVE-N531 for the treatment of patients with DMD amenable to exon 53 skipping; an average dystrophin expression of 7.8% was achieved. The Duchenne Muscular Dystrophy market, in the 7 major markets, will reach $5.2 billion by 2033. Positive FDA meeting held; potential for WVE to file for Accelerated Approval of WVE-N531 for DMD patients amenable to Exon 53 skipping in 2026. Read the full article on Seeking Alpha
새 내러티브 • Mar 23
WVE-007 And WVE-006 Will Offer New Treatment Options For Obesity And AATD
Advancing innovative treatments like WVE-007 and WVE-006 could drive revenue growth by addressing current therapy limitations and capturing market share in obesity and AATD.Seeking Alpha • Jan 08
Wave Life Sciences Is A Buy On Pipeline Prospects
Summary Wave Life Sciences develops stereopure oligonucleotides targeting genetic mutations, with lead assets in DMD, AATD, and Huntington's Disease showing promising data. Major collaborations with GSK and positive trial results have significantly boosted WVE's stock, despite previous flat performance and management missteps. Financially strong with $525M in cash, the Company has a solid runway for 8–10 quarters, though approval for its programs is still years away. Despite valuation risks, WVE's successful data, collaborations, and large target markets make it a buy; start small, accumulate at dips, and hold long term. Read the full article on Seeking Alpha분석 기사 • Nov 15
US$22.20 - That's What Analysts Think Wave Life Sciences Ltd. (NASDAQ:WVE) Is Worth After These Results
Wave Life Sciences Ltd. ( NASDAQ:WVE ) missed earnings with its latest quarterly results, disappointing...분석 기사 • Nov 09
Optimistic Investors Push Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Up 95% But Growth Is Lacking
Despite an already strong run, Wave Life Sciences Ltd. ( NASDAQ:WVE ) shares have been powering on, with a gain of 95...Seeking Alpha • Oct 16
Wave Life Sciences: Positive WVE-006 Data For AATD Leads To 2025 Catalyst
Summary Wave Life Sciences announced positive results from its phase 1b/2a RestorAAtion-2 study using WVE-006 for the treatment of alpha-1 antitrypsin deficiency patients. A single subcutaneous administration of 200 mg of WVE-006 resulted in the presence of wild-type alpha-1 antitrypsin protein; This led to a more than 60% increase of AAT. The global Alpha-1 Antitrypsin Deficiency market is expected to reach a $10 billion market value by 2033. Additional results from the phase 1b/2a RestorAAtion-2 study using WVE-006 for the treatment of patients with alpha-1 Antitrypsin Deficiency, expected in 2025. Read the full article on Seeking Alpha분석 기사 • Sep 25
There's Reason For Concern Over Wave Life Sciences Ltd.'s (NASDAQ:WVE) Massive 43% Price Jump
Despite an already strong run, Wave Life Sciences Ltd. ( NASDAQ:WVE ) shares have been powering on, with a gain of 43...Seeking Alpha • Sep 24
Wave Life Sciences: Spiking On Strong DMD Data, But Not Fully De-Risked Yet
Summary Wave Life Sciences stock surged over 50% today due to promising data from its Duchenne Muscular Dystrophy candidate WVE-N531, showing >5% dystrophin production. The safety profile of WVE-N531 is strong, but competition from gene therapies and the need for further efficacy data present significant challenges. Investors should consider waiting for 48-week data and clearer regulatory paths before committing, despite WVE stock's current upside potential. Despite past setbacks, Wave's innovative RNA-targeting technology and strategic partnerships, like with GSK, position it for potential breakthroughs in multiple disease areas. A successfully approved DMD candidate could ultimately turn Wave into a double-digit billion company, like rival Sarepta Therapeutics, but that eventuality remains a long way off. Read the full article on Seeking Alpha분석 기사 • Sep 08
Broker Revenue Forecasts For Wave Life Sciences Ltd. (NASDAQ:WVE) Are Surging Higher
Shareholders in Wave Life Sciences Ltd. ( NASDAQ:WVE ) may be thrilled to learn that the analysts have just delivered a...분석 기사 • Aug 05
We're Keeping An Eye On Wave Life Sciences' (NASDAQ:WVE) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...분석 기사 • Jun 25
Pinning Down Wave Life Sciences Ltd.'s (NASDAQ:WVE) P/S Is Difficult Right Now
You may think that with a price-to-sales (or "P/S") ratio of 5.7x Wave Life Sciences Ltd. ( NASDAQ:WVE ) is a stock to...분석 기사 • Apr 09
We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Mar 09
Wave Life Sciences' Weighty Ambition: Carving Out Obesity Niche
Summary Wave Life Sciences is entering the obesity market, selecting INHBE as a clinical candidate. The company faces intense competition from other RNA-based therapeutics companies, such as Alnylam, that have successfully brought treatments to market. Investment recommendation: Hold, due to intense competition, financial sustainability concerns, and current market sentiment. Read the full article on Seeking Alpha분석 기사 • Mar 03
Wave Life Sciences Ltd.'s (NASDAQ:WVE) 30% Price Boost Is Out Of Tune With Revenues
Wave Life Sciences Ltd. ( NASDAQ:WVE ) shareholders are no doubt pleased to see that the share price has bounced 30% in...분석 기사 • Sep 13
We're Interested To See How Wave Life Sciences (NASDAQ:WVE) Uses Its Cash Hoard To Grow
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...분석 기사 • May 08
Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Cut Their EPS Forecasts Substantially
One thing we could say about the analysts on Wave Life Sciences Ltd. ( NASDAQ:WVE ) - they aren't optimistic, having...분석 기사 • Mar 30
Here's Why Wave Life Sciences (NASDAQ:WVE) Must Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, Wave Life Sciences...분석 기사 • Jan 20
Are Investors Undervaluing Wave Life Sciences Ltd. (NASDAQ:WVE) By 47%?
Key Insights Wave Life Sciences' estimated fair value is US$8.4 based on 2 Stage Free Cash Flow to Equity Current share...이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2028 | 109 | -256 | -286 | -245 | 13 |
| 12/31/2027 | 52 | -244 | -272 | -238 | 16 |
| 12/31/2026 | 57 | -185 | -242 | -105 | 15 |
| 3/31/2026 | 72 | -184 | -185 | -184 | N/A |
| 12/31/2025 | 43 | -204 | -188 | -187 | N/A |
| 9/30/2025 | 109 | -122 | -198 | -197 | N/A |
| 6/30/2025 | 94 | -130 | -200 | -199 | N/A |
| 3/31/2025 | 105 | -112 | -181 | -181 | N/A |
| 12/31/2024 | 108 | -97 | -152 | -151 | N/A |
| 9/30/2024 | 54 | -143 | -142 | -141 | N/A |
| 6/30/2024 | 111 | -73 | -130 | -129 | N/A |
| 3/31/2024 | 113 | -62 | -139 | -138 | N/A |
| 12/31/2023 | 113 | -58 | -21 | -19 | N/A |
| 9/30/2023 | 85 | -85 | -21 | -20 | N/A |
| 6/30/2023 | 37 | -131 | -12 | -11 | N/A |
| 3/31/2023 | 15 | -151 | -4 | -2 | N/A |
| 12/31/2022 | 4 | -162 | -129 | -128 | N/A |
| 9/30/2022 | 4 | -153 | -103 | -101 | N/A |
| 6/30/2022 | 40 | -120 | -105 | -104 | N/A |
| 3/31/2022 | 43 | -118 | -85 | -84 | N/A |
| 12/31/2021 | 41 | -122 | -90 | -89 | N/A |
| 9/30/2021 | 49 | -116 | -114 | -113 | N/A |
| 6/30/2021 | 16 | -143 | -106 | -105 | N/A |
| 3/31/2021 | 16 | -145 | -135 | -134 | N/A |
| 12/31/2020 | 20 | -150 | -117 | -116 | N/A |
| 9/30/2020 | 13 | -178 | -148 | -146 | N/A |
| 6/30/2020 | 13 | -196 | -172 | -169 | N/A |
| 3/31/2020 | 17 | -197 | -168 | -164 | N/A |
| 12/31/2019 | 16 | -194 | N/A | -188 | N/A |
| 9/30/2019 | 17 | -175 | N/A | -160 | N/A |
| 6/30/2019 | 19 | -162 | N/A | -145 | N/A |
| 3/31/2019 | 16 | -156 | N/A | -41 | N/A |
| 12/31/2018 | 14 | -147 | N/A | -23 | N/A |
| 9/30/2018 | 12 | -140 | N/A | -13 | N/A |
| 6/30/2018 | 9 | -127 | N/A | -7 | N/A |
| 3/31/2018 | 5 | -116 | N/A | -99 | N/A |
| 12/31/2017 | 4 | -102 | N/A | -84 | N/A |
| 9/30/2017 | 3 | -90 | N/A | -74 | N/A |
| 6/30/2017 | 3 | -82 | N/A | -63 | N/A |
| 3/31/2017 | 2 | -69 | N/A | -42 | N/A |
| 12/31/2016 | 1 | -56 | N/A | -32 | N/A |
| 9/30/2016 | 1 | -44 | N/A | -25 | N/A |
| 6/30/2016 | 0 | -31 | N/A | -16 | N/A |
| 3/31/2016 | 0 | -24 | N/A | -18 | N/A |
| 12/31/2015 | 0 | -19 | N/A | -13 | N/A |
| 9/30/2015 | 0 | -14 | N/A | -7 | N/A |
| 6/30/2015 | 0 | -10 | N/A | -5 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: WVE 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 vs 시장: WVE 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
고성장 수익: WVE 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 대 시장: WVE 의 수익(연간 45.6%)이 US 시장(연간 11.5%)보다 빠르게 성장할 것으로 예상됩니다.
고성장 매출: WVE 의 수익(연간 45.6%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: WVE는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/07 01:27 |
| 종가 | 2026/05/07 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Wave Life Sciences Ltd.는 29명의 분석가가 다루고 있습니다. 이 중 16명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Alec Stranahan | BofA Global Research |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Whitney Ijem | Canaccord Genuity |